semaglutide glucose regulation Before & After GLP-1 Weight Loss Semaglutide from Bench to Bedside:

At 2.4 mg, the target dose for phase 3 trials, the benefit-to-risk ratio appeared optimal

Stomach Paralysis The FDA has received reports of certain patients using semaglutide, encountering severe gastroparesis, commonly referred toas stomach paralysis. This condition leads to a significant slowing down of food digestion, potentially resulting in intense vomiting and nausea

Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P et al

This monitoring should include regular assessment of the condition being treated as well as systematic screening for potential adverse effects or complications